Clinical biometrics has always sat at the center of drug development. What’s changed in 2026 is where it sits in the timeline. For decades, biometrics operated at the back end
The clinical research industry is under increasing pressure to accelerate drug development, reduce trial costs, ensure regulatory compliance, and deliver innovative treatments to patients faster than ever before. As clinical
A Phase III dataset with a clean audit trail and a shaky one can look identical on the surface. The difference only shows up when an FDA reviewer or an